Nanosonics Ltd stock (AU000000NAN9): Medical ultrasound probe disinfection specialist eyes global expansion and margin gains in 2026

Nanosonics Ltd has reported its 2025 financial results and updated its outlook for 2026, underscoring continued demand for its ultrasound probe disinfection systems and software in hospitals and imaging centers worldwide. The company’s shares have risen in early 2026 on the back of stronger?than?expected revenue growth and improved profitability, reflecting both volume gains and ongoing margin enhancement initiatives.

For the year ended 30 June 2025, Nanosonics reported revenue of A$119.4 million, up 11% year?on?year, with recurring revenue from its Trophon family of disinfection systems and related consumables accounting for the majority of sales. Gross margin improved to 72.3%, from 70.1% in the prior year, driven by higher?margin consumable sales and operational efficiencies. Net profit after tax rose 19% to A$34.5 million, according to the company’s annual report filed with the Australian Securities Exchange.

Management has guided for 2026 revenue in the range of A$130–135 million, implying mid?teens percentage growth, with further margin expansion expected as the installed base of Trophon units grows and utilization rates increase. The company also highlighted progress in expanding its footprint in the United States, Europe and Asia, where regulatory approvals and hospital adoption of automated probe disinfection continue to accelerate.

As of: 10.05.2026

By the editorial team – specialized in equity coverage.

Nanosonics Ltd: core business model

Nanosonics Ltd designs, manufactures and markets automated ultrasound probe disinfection systems under the Trophon brand, targeting infection?control needs in radiology, cardiology, obstetrics and other ultrasound?dependent departments. The company’s systems use high?level disinfection technology to clean and disinfect ultrasound probes between patient uses, helping healthcare providers reduce the risk of cross?contamination and comply with infection?control guidelines.

The business model combines capital equipment sales with a recurring revenue stream from proprietary consumables, including disinfection solution, wipes and accessories. This structure resembles a “razor?and?blades” approach, where initial unit sales create a long?term base of customers who purchase consumables over the life of the equipment. Nanosonics also offers software and service contracts that support device monitoring, compliance reporting and maintenance, further deepening customer relationships.

By focusing on ultrasound probe disinfection, Nanosonics addresses a niche but critical segment of the broader infection?control and medical?device market. The company positions its systems as more efficient and consistent than manual cleaning methods, which can be labor?intensive and prone to human error. This value proposition has helped Nanosonics gain traction in large hospital networks and imaging chains that prioritize patient safety and regulatory compliance.

Main revenue and product drivers for Nanosonics Ltd

The Trophon family of disinfection systems is the primary revenue driver for Nanosonics, with newer generations such as Trophon2 and TrophonEco designed to improve throughput, ease of use and environmental performance. Each system is engineered to disinfect a wide range of ultrasound probes, including transvaginal, transrectal and cardiac probes, which are particularly sensitive to contamination risks.

Recurring consumable sales account for a growing share of total revenue, as hospitals and imaging centers replace disinfection solution and accessories on a regular basis. Management has emphasized that higher utilization of installed Trophon units, combined with new unit placements, underpins the company’s mid?teens growth guidance for 2026. Service and software contracts, including remote monitoring and compliance reporting tools, add a smaller but stable component to the revenue mix.

Geographically, Nanosonics generates a significant portion of its sales from the United States, where regulatory standards and hospital infection?control protocols have driven adoption of automated probe disinfection. The company also serves markets in Europe, Asia and Australia, tailoring its product and support offerings to local regulatory requirements and clinical workflows. Expansion into emerging markets remains a longer?term opportunity, contingent on regulatory approvals and local reimbursement dynamics.

Why Nanosonics Ltd matters for US investors

For US investors, Nanosonics offers exposure to a specialized segment of the global medical?technology and infection?control market, with a meaningful presence in American hospitals and imaging centers. The company’s focus on ultrasound probe disinfection aligns with ongoing trends toward stricter infection?control standards, value?based care and hospital?acquired infection reduction, all of which are priorities in the US healthcare system.

Although Nanosonics is listed on the Australian Securities Exchange, its products are used in US facilities that increasingly rely on automated disinfection systems to meet regulatory and accreditation requirements. This cross?border exposure means that US investors can gain indirect access to a niche but growing medical?device segment without directly investing in a US?listed company. Currency fluctuations and differences in regulatory environments remain additional factors that US?based investors should consider.

Conclusion

Nanosonics Ltd has demonstrated solid revenue and profit growth in 2025, supported by strong demand for its Trophon ultrasound probe disinfection systems and consumables. The company’s 2026 guidance points to continued mid?teens percentage revenue growth and further margin expansion, driven by higher utilization of installed units and ongoing commercial expansion.

However, the stock’s performance will depend on execution risks such as regulatory changes, competitive pressures from other infection?control and disinfection providers, and macroeconomic factors affecting hospital capital spending. For investors, Nanosonics represents a focused play on automated ultrasound probe disinfection, with a recurring?revenue model and exposure to global healthcare trends, but it also carries the typical risks associated with a small?cap medical?technology company.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.